Format

Send to

Choose Destination
mSphere. 2017 Oct 4;2(5). pii: e00397-17. doi: 10.1128/mSphere.00397-17. eCollection 2017 Sep-Oct.

A New Take on an Old Remedy: Generating Antibodies against Multidrug-Resistant Gram-Negative Bacteria in a Postantibiotic World.

Author information

1
Division of Infectious Diseases, Department of Medicine, Stony Brook University, Stony Brook, New York, USA.
2
Department of Molecular Genetics and Microbiology, Stony Brook University, Stony Brook, New York, USA.

Abstract

With the problem of multidrug-resistant Gram-negative pathogens becoming increasingly dire, new strategies are needed to protect and treat infected patients. Though abandoned in the past, monoclonal antibody therapy against Gram-negative bacteria remains a potential solution and has potential advantages over the broad-spectrum antibiotics they were once replaced by. This Perspective reviews the prospect of utilizing monoclonal antibody therapy against these pathogens, as well as the challenges of doing so and the current therapy targets under investigation.

KEYWORDS:

Acinetobacter; Enterobacteriaceae; Escherichia coli; Klebsiella; MAb therapy; ST258; monoclonal antibodies; multidrug resistance

Supplemental Content

Full text links

Icon for American Society for Microbiology Icon for PubMed Central
Loading ...
Support Center